PARP Inhibition as a Promising Option to Treat RB1 Deficient Osteosarcoma, Which Demonstrates Marked Vulnerability

George Li Introduction:  Osteosarcoma is the most common primary bone malignancy in pediatric patients that often aggressively metastasizes if improperly managed. 1 Current early phase clinical trials are focused on modification of current antineoplastic agents, but have only managed to demonstrate that they are tolerable with questionable efficacy. 2 Poly-ADP-Ribose-Polymerase…
Uncategorized